Effects of route and coadministration of recombinant raccoon poxviruses on immune responses and protection against highly pathogenic avian influenza in mice

Vaccine

Volumn 30, Issue 45, 2012, Pages 6402-6408

  Kingstad Bakke, Brock ^a   Brewoo, Joseph N ^a   Mai, Le Quynh ^b   Kawaoka, Yoshihiro ^a,c,d   Osorio, Jorge E ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b NATIONAL INSTITUTE OF HYGIENE AND EPIDEMIOLOGY   (Viet Nam)

^c UNIVERSITY OF TOKYO   (Japan)

^d KOBE UNIVERSITY   (Japan)

Author keywords

HPAI; Mice; Mucosal; Raccoon poxvirus; Vaccine

Indexed keywords

ESCHERICHIA COLI ENTEROTOXIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT RACCOON POXVIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS HEMAGGLUTININ; VIRUS SIALIDASE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; AVIAN INFLUENZA VIRUS; CHICKEN; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; INFLUENZA VIRUS A H5N1; LOW DRUG DOSE; MORBIDITY; MOUSE; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; RACCOON POXVIRUS; VACCINATION; VIRUS RECOMBINANT;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INJECTIONS, INTRADERMAL; MICE; MICE, INBRED A; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; POXVIRIDAE; VACCINATION;

EID: 84866494066     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.08.018     Document Type: Article

References (24)

1. Loeffelholz M.J. Avian influenza A H5N1 virus. Clin Lab Med 2010, 30(1):1-20.
2. Meltzer M.I., Cox N.J., Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis 1999, 5(September-October (5)):659-671.
3. Guan Y., Smith G.J.D., Webby R., Webster R.G. Molecular epidemiology of H5N1 avian influenza. Rev Sci Tech 2009, 28(1):39-47.
4. Kopecky-Bromberg S.A., Palese P. Recombinant vectors as influenza vaccines. Curr Top Microbiol Immunol 2009, 333:243-267.
5. Poon L.L.M., Leung Y.H.C., Nicholls J.M., Perera P-Y., Lichy J.H., Yamamoto M., et al. Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice. J Immunol 2009, 182(5):3063-3071.
6. Tumpey T.M., Alvarez R., Swayne D.E., Suarez D.L. Diagnostic approach for differentiating infected from vaccinated poultry on the basis of antibodies to NS1, the nonstructural protein of influenza A virus. J Clin Microbiol 2005, 43(2):676-683.
7. Rimmelzwaan G.F., Sutter G. Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara. Expert Rev Vaccines 2009 Apr, 8(4):447-454.
8. Veits J., Romer-Oberdorfer A., Helferich D., Durban M., Suezer Y., Sutter G., et al. Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditions. Vaccine 2008, 26(March (13)):1688-1696.
9. Gherardi M.M., Esteban M. Recombinant poxviruses as mucosal vaccine vectors. J Gen Virol 2005, 86(November (11)):2925-2936.
10. Carroll M.W., Moss B. Poxviruses as expression vectors. Curr Opin Biotechnol 1997, 8(October (5)):573-577.
11. Hwa S.H., Iams K.P., Hall J.S., Kingstad B.A., Osorio J.E. Characterization of recombinant raccoonpox vaccine vectors in chickens. Avian Dis 2010, 54(December (4)):1157-1165.
12. Moss B. Poxvirus vectors: cytoplasmic expression of transferred genes. Curr Opin Genet Dev 1993, 3(February (1)):86-90.
13. Gao W., Soloff A.C., Lu X., Montecalvo A., Nguyen D.C., Matsuoka Y., et al. Protection of mice and poultry from lethal h5n1 avian influenza virus through adenovirus-based immunization. J Virol 2006, 80(February (4)):1959-1964.
14. WHO WHO manual on avian influenza: diagnosis and surveillance 2002, WHO, Geneva, Switzerland.
15. DiNapoli J.M., Nayak B., Yang L., Finneyfrock B.W., Cook A., Andersen H., et al. Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. J Virol 2010, 84(3):1489-1503.
16. Rosner B. Fundamentals of biostatistics 1995, Duxbury Press, Belmnont, CA.
17. Rocke T.E., Iams K.P., Dawe S., Smith S.R., Williamson J.L., Heisey D.M., et al. Further development of raccoon poxvirus-vectored vaccines against plague (Yersinia pestis). Vaccine 2009, 28(December (2)):338-344.
18. Rocke T.E., Pussini N., Smith S.R., Williamson J., Powell B., Osorio J.E. Consumption of baits containing raccoon pox-based plague vaccines protects black-tailed prairie dogs (Cynomys ludovicianus). Vector borne and zoonotic diseases (Larchmont, NY) 2010, 10(January-February (1)):53-58.
19. La Gruta N.L., Kedzierska K., Stambas J., Doherty P.C. A question of self-preservation: immunopathology in influenza virus infection. Immunol Cell Biol 2007, 85(2):85-92.
20. Matsuoka T., Okamoto Y., Matsuzaki Z., Endo S., Ito E., Tsutsumi H., et al. Characteristics of immunity induced by viral antigen or conferred by antibody via different administration routes. Clin Exp Immunol 2002, 130(3):386-392.
21. Couch R.B., Kasel J.A. Immunity to influenza in man. Annu Rev Microbiol 1983, 37:529-549.
22. Liew F.Y., Russell S.M., Appleyard G., Brand C.M., Beale J. Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity. Eur J Immunol 1984, 14(4):350-356.
23. Perera L.P., Goldman C.K., Waldmann T.A. Comparative assessment of virulence of recombinant vaccinia viruses expressing IL-2 and IL-15 in immunodeficient mice. Proc Natl Acad Sci USA 2001, 98(9):5146-5151.
24. Hutchings C.L., Birkett A.J., Moore A.C., Hill A.V.S. Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge. Infect Immun 2007, 75(12):5819-5826.